Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cultured chondrocytes - Vericel

Next Previous
X
Search
Drug Profile

Autologous cultured chondrocytes - Vericel

Alternative Names: Articel; Autologous cultured chondrocytes on porcine collagen membrane; MACI; MACI ArthroTM; MACI Implant; Matrix-applied-characterised-autologous-cultured-chondrocytes-Vericel; Matrix-induced autologous chondrocyte implant

Latest Information Update: 16 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verigen AG
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries
  • Phase II Osteonecrosis

Most Recent Events

  • 26 Aug 2024 Registered for Knee injuries (In adolescents, In adults) in USA (Parenteral)
  • 08 Mar 2024 Withdrawn for Knee injuries in Australia (Parenteral) (Vericel Corporation SEC filing, Form 10-K, March 2024)
  • 01 Mar 2024 Preregistration for Knee injuries (In adolescents, In children) in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top